The latest people and business news of the industry, all in one place.
ActiGraph has announced the hiring of Mitchell Bayer as Global Vice President of Partner Sales, and Robin Root as Vice President of Operations.
Calyx has appointed Dr. Stephen M. Bravo as its Chief Medical Officer.
Worldwide Clinical Trials announced that Sherilyn Adcock, RPH, PHD, has been promoted to chief scientific officer, Early Phase Development.
Medable announced the hiring of Sina Mossayeb as chief design officer.
Tools4Patient named Delphine Elmerich as Quality Assurance Director.
Medable announced the hiring of Dr. Pamela Tenaerts as Chief Scientific Officer.
MedVector announces that it has appointed John Neal, as strategic advisor, pharma relations and clinical protocol.
Metrics Contract Services has announced Stephanie Emory, PhD as Associate Director of Pharmaceutical Development.
Cognizant has been recognized by Everest Group as one of the top global companies providing Pharmacovigilance and Complaint Management Operations services.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.